Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

MRNS Marinus Pharmaceuticals Inc

0,3299

0,0076 (2,36%)

23 Nov 2024 - Fermé

Retardé de 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Marinus Pharmaceuticals (NASDAQ:MRNS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

Plus de graphiques de la Bourse Marinus Pharmaceuticals

Marinus Pharmaceuticals (NASDAQ:MRNS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024

Plus de graphiques de la Bourse Marinus Pharmaceuticals

Actualités Marinus Pharmaceuticals Inc

Form 8-K - Current report
Vendredi 15 Novembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Vendredi 15 Novembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jeudi 14 Novembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jeudi 14 Novembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jeudi 14 Novembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mardi 12 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Mardi 12 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Mardi 12 Novembre 2024 ( il y a 2 semaines) • Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Samedi 2 Novembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Jeudi 24 Octobre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Jeudi 24 Octobre 2024 ( il y a 1 mois) • Business Wire

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
Jeudi 17 Octobre 2024 ( il y a 1 mois) • Business Wire

Plus d'articles sur Marinus Pharmaceuticals Inc

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales